Sequence: RQIKIWFQNRRMKWKK
| Experiment Id | EXP001537 |
|---|---|
| Paper | Intracellular delivery of antiviral shRNA using penetratin-based complexes effectively inhibits resp |
| Peptide | Penetratin (PEN) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Not reported (prepared at penetratin:plasmid molar ratio 20:1; complexation in HEPES-buffered saline) |
| Rna Concentration | Not reported (50 µL complex added to cells; plasmid dose not explicitly stated in methods excerpt) |
| Mixing Ratio | molar ratio 20:1 (penetratin:plasmid/shRNA vector) |
| Formulation Format | noncovalent CPP/DNA complexes (electrostatic) |
| Formulation Components | Penetratin + pGFP-V-RS (RSV F-shRNA + GFP) plasmid |
| Size Nm | 164.00 |
| Zeta Mv | 8.70 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HEp-2 (human laryngeal epidermoid carcinoma) infected with RSV A2 (MOI 0.1) |
| Animal Model | |
| Administration Route | |
| Output Type | Antiviral activity (RSV F gene copy number by qPCR; viral titer by plaque assay) + transfection efficiency (GFP, flow cytometry) |
| Output Value | Transfection efficiency ~93% (48 h); RSV F gene copies reduced from 8.8×10^5 (untreated) to 5.45×10^3; viral titer reduced from 1.8×10^6 PFU/mL to 8.3×10^4 PFU/mL (24–48 h windows as reported) |
| Output Units | |
| Output Notes | Complexation optimal at 20:1 by gel shift; penetratin-shRNA reduced syncytia/CPE, viral RNA (F gene), and progeny virus production in HEp-2 supernatants. |
| Toxicity Notes | No significant cytotoxicity vs untreated in HEp-2 (MTT) for penetratin-shRNA (20:1 and 25:1) up to 72 h. |
| Curation Notes |